A Disease Area Study on the Awareness and Perceptions of Systemic Inflammation and hsCRP as a biomARKer in Patients With ASCVD and CKD in China Among Cardiologists and Nephrologists

NCT06589791 | Completed

• 2 other identifiers: DAS-8091U1111-1303-3098
• Study Type: observational
• Target: 1,500
• Locations: 1 country
• Sites: 1

Brief Summary

This is a survey-based study with the objective to understand the awareness, perceptions and potential clinical management patterns among Chinese cardiologists and nephrologists towards the role of systemic inflammation in patients with ASCVD and CKD in real-world clinical setting.

Conditions

Atherosclerotic Cardiovascular Disease (ASCVD); Chronic Kidney Disease (CKD)

Outcome Measures

Primary Outcomes (1)

• Health care professional's perceptions towards the role of systemic inflammation in the identification, treatment and management of patients with ASCVD and CKD

  Multi-select from a defined list; Single-select from a defined list; Numerical; 7-point Likert scale for measurement of agreement to different statements from 1 "strongly disagree" to 7 "strongly agree"

  At the time of survey response (Day 1)

Study Arms (1)

Health care professionals

Cardiologists and nephrologists in China

Other: No treatment given

Interventions

No treatment given OTHER

Online self-completion survey

Health care professionals

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Cardiologists and nephrologists with patients that have ASCVD and CKD in China

You may qualify if:

• Work in cardiology, internal medicine, or nephrology department
• Specialize in one of the following: coronary interventional cardiology, HF, general cardiology, preventive cardiology, cardiac rehabilitation or nephrology
• Practice at consultant level for 3+ years after standardized training for resident physicians or 3+ years' working experience as a specialist
• Manage at least 20 adult patients with ASCVD and CKD (not dialysis-only) every month

You may not qualify if:

• Unwilling to provide informed consent
• Insufficient number of patients with ASCVD and CKD

Sponsors & Collaborators

• Novo Nordisk A/S: lead

Study Sites (1)

Novo Nordisk Shanghai Pharmaceuticals Co., Ltd

Shanghai, China

Location

MeSH Terms

Conditions

Atherosclerosis; Renal Insufficiency, Chronic

Condition Hierarchy (Ancestors)

Arteriosclerosis; Arterial Occlusive Diseases; Vascular Diseases; Cardiovascular Diseases; Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms

Study Officials

• Clinical Transparency dept. 2834

  Novo Nordisk A/S

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 6, 2024
• First Posted: September 19, 2024
• Study Start: September 9, 2024
• Primary Completion: December 5, 2024
• Study Completion: December 5, 2024
• Last Updated: December 5, 2025

Record last verified: 2025-11

Data Sharing

• IPD Sharing: Will share

Locations

CN (1)